Drug Approval | April 18, 2022
Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Subscribe To Our Newsletter & Stay Updated
